GFAP and Alzheimer disease: We hypothesized that a combination of the current key plasma biomarkers Abeta42/40, P‐tau, GFAP, and NfL can aid in (early) AD, FTD, or DLB diagnosis and in differential diagnosis of AD versus FTD or DLB in the daily clinical dementia practice.